Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.38 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.38 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30359459 | 1.00 | MAP4K4 (0.38) | MAP4K4MAPK9CSNK1A1CSNK1DMINK1 | |
| SCHEMBL25206204 | 0.90 | MAPK14 (0.40) | MAP4K4KDM4ENPC1HCRTR1USP2 | |
| SCHEMBL30359478 | 0.90 | MAPK14 (0.40) | MAP4K4KDM4ENPC1HCRTR1USP2 | |
| SCHEMBL25205150 | 0.83 | MAPK1 (0.41) | MAP4K4KDM4ENPC1HCRTR1USP2 | |
| SCHEMBL25238696 | 0.83 | ALDH1A1 (0.40) | MAP4K4PRKD3GSK3AGSK3BAURKB | |
| SCHEMBL30359461 | 0.83 | ALDH1A1 (0.40) | MAP4K4PRKD3GSK3AGSK3BAURKB | |
| SCHEMBL25206143 | 0.82 | KDM4E (0.38) | MAP4K4KDM4ENPC1HCRTR1USP2 | |
| SCHEMBL30359474 | 0.82 | KDM4E (0.38) | MAP4K4KDM4ENPC1HCRTR1USP2 | |
| SCHEMBL25528944 | 0.81 | KDM4E (0.36) | MAP4K4MAPK9CSNK1A1CSNK1DMINK1 | |
| SCHEMBL25255165 | 0.80 | MAP4K4 (0.40) | MAP4K4KDM4ENPC1HCRTR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2025-04-17 | — | — | US | claimed |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | CROSSIGNAL THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | claimed |
| WO-2023091604-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2023-05-25 | — | — | US | claimed |
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | CROSSIGNAL THERAPEUTICS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| WO-2023091604-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091604-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | CROSSIGNAL THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122203-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | MAP4K4 3318/4885MAPK9 4277/4885CSNK1A1 2301/4885 |
| US-20230159541-A1 | ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | MAP4K4 3318/4885MAPK9 4277/4885CSNK1A1 2301/4885 |
| US-12065444-B2 | Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists | ADORA2A, ADORA1, P2RX5 | MAP4K4 3222/4885MAPK9 4269/4885CSNK1A1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.